COMPANY PROFILE

Cello Therapeutics

Explore full profile

A biotechnology company that specializes in the development of nanoparticles for cancer treatment

San Diego, United StatesFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Cello Therapeutics

Cello Therapeutics, based in San Diego, California, is a pioneering biomedical company founded in 2016. The company specializes in developing biomimetic cell membrane-coated nanoparticles designed for cancer drug delivery. By leveraging the natural properties of cellular membranes, Cello's technology provides a stealth coating for nanoparticles, enhancing their ability to deliver drugs effectively to cancer cells.

Cello's innovative approach has demonstrated promising results in multiple animal studies, showing an 85-100% survival rate and long-term immunity for treating solid tumors with nanoparticles loaded with immunotherapy agents. The company operates in the biotech sector, focusing on creating breakthrough nanomedicines that revolutionize chemotherapy and immunotherapy treatments.

Cello Therapeutics primarily serves the healthcare market, targeting oncology patients and medical institutions seeking advanced cancer treatment solutions. The business model revolves around the research, development, and commercialization of its proprietary nanoparticle delivery platforms. Revenue is generated through the sale of these specialized nanomedicines and potential partnerships or licensing agreements with pharmaceutical companies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: San Diego, United States
Employees: 3
Open positions: None listed
Dealroom signal: 28.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Testing, Biotechnology, Oncology, Spinout, Biotech and Pharma, medical testing, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Aug 2022	$20M	$80M	Undisclosed	↗
SEED✓Equity / VC	Jun 2017	$1.6M	$6.4M	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Cello Therapeutics website traffic

Latest recorded traffic for Cello Therapeutics is 120 monthly website visits, down 85.5% over the last three months. Cello Therapeutics's team declined 40% over the past year.

Latest monthly visits120 3-month web change-85.5% 1-year team growth-40%

Monthly website visitsOct 2017–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SYSyantraPrecision healthcare company that focuses on the commercialization of breast cancer detection blood tests	Calgary, Canada	Operational	16	$10M	$14M
MTMetabolomic TechnologiesCommitted to developing non-invasive in-vitro diagnostics to meet patients' greatest unmet needs	Edmonton, Canada	Operational
CTCARsgen TherapeuticsA leading immunotherapy company focused on the development of new chimeric antigen receptor	Xuhui District, China	Operational
SGSinglera GenomicsA developer of 'liquid biopsy' analysis reagents and software, focusing on determing methylation haplotypes across many thousands of genomic locations in cell-free DNA	San Diego, United States	Operational
RPRedPath Integrated PathologyA growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics	Pittsburgh, United States	Acquired
BTBioAffinity TechnologiesA cancer diagnostics company that develops non-invasive, early-stage diagnostics to detect cancer and diseases	San Antonio, United States	Operational
LLLeuko LabsDeveloping the first device for non-invasive white cell monitoring	Boston, United States	Operational
HAHalioDxProviding oncologists and biopharma with first-in-class immune-based diagnostic products and services	Marseille, France	Acquired